Medtronic appoints Ingrid Goldberg as vice president and head of investor relations; Ryan Weispfenning to join Diabetes to lead investor relations for MiniMed, the planned new[...]

Medtronic plc, a global leader in healthcare technology, today announced that Ryan Weispfenning, vice president and head of investor relations, has elected to join its Diabetes business to establish and lead the investor relations function for MiniMed, the planned New Diabetes Company. Ryan brings over 25 years of experience with Medtronic to his new role. He has been a member of the Medtronic investor relations team for the past 17 years, including leading the function for more than a decade. He helped guide the company through dynamic business environments while fostering strong relationships with analysts, investors, and other stakeholders around the world. He will be a key strategic partner to the MiniMed executive team and board of directors, and his experience and leadership will be important for both Medtronic and MiniMed as the business works toward its intended separation of MiniMed into an independent, publicly traded company.

"After leading Medtronic investor relations for the past decade, I am now honored to help establish the investor relations function for MiniMed as we prepare for its intended separation into an independent, public company," said Ryan Weispfenning. "This is a pivotal moment for the Diabetes business, and I look forward to partnering with the MiniMed leadership team and engaging with the investor community to articulate our long-term strategy, growth opportunities, and commitment to improving outcomes for people living with diabetes worldwide."

The company also announced that Ingrid Goldberg will join Medtronic as vice president and head of investor relations. Goldberg brings more than 20 years of industry experience, spanning the financial, medical device, and life science sectors.

Most recently, Goldberg served as vice president of finance and investor relations at Novocure, where she led the investor relations, communications, and business development functions. Prior to Novocure, Goldberg held leadership positions at Abiomed, leading investor relations through a period of exceptional expansion and contributing to the company's more than 15x increase in market capitalization. Goldberg also led the investor relations function at gene and cell therapy pioneer, Bluebird Bio. Before transitioning to corporate healthcare, Goldberg spent a decade at Bank of America Merrill Lynch.

Goldberg holds degrees from Princeton University and the MIT Sloan School of Management. She will be based in Boston, where she lives with her husband, Scott, and their two daughters.

"I am thrilled to join Medtronic, an organization whose work transforms patient lives every day," said Goldberg. "The company's compelling product portfolio is inspiring, and I am eager to share the progress and innovation that define Medtronic and the people we serve. It is a privilege to contribute to a company so deeply committed to improving human health."

These changes will be effective on Dec. 8. Ryan will support Ingrid and Medtronic for a period of time to ensure a seamless transition.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission - to alleviate pain, restore health, and extend life - unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to make diabetes more predictable, so everyone can embrace life to the fullest with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:

Erika Winkels
Public Relations
+1-612-558-8932

Ryan Weispfenning
Investor Relations
+1-763-505-4626